Skip to main content

Table 1 Patients’ characteristics depending on the plasma AGE-related fluorescence (FL).a

From: Prognostic Potential and Tumor Growth-Inhibiting Effect of Plasma Advanced Glycation End Products in Non-Small Cell Lung Carcinoma

NSCLC patients parameter

 

Plasma FL

 

Data

Lowb (n = 36)

Highb (n = 34)

P valuec

Plasma FL, μg/mL AGE-BSA

M

0.81 (0.73–0.95)

1.29 (1.21–1.61)

<0.001

Age, y

M

69 (60–72)

68 (60–73)

0.797

Gender

    

Male

n

31

22

0.071

Female

n

5

12

 

Body mass index

M

26 (24–28)

27 (24–29)

0.813

NSCLC histology

    

ADCd

n

11

19

0.059

SCCe

n

21

12

 

Others

n

4

4

 

Tumor (T) stage

    

T1

n

5

12

0.113

T2

n

20

14

 

T3-4

n

11

8

 

Nodal (N) stage

    

N0

n

15

21

0.290

N1

n

9

6

 

N2

n

11

7

 

Resection (R) stage

    

R0

n

31

33

0.199

R1

n

5

1

 

Smoker

    

Current

n

18

12

0.199

Former

n

12

16

 

None

n

6

6

 

Diabetes mellitus

    

Yes

n

10

9

1.000

No

n

26

29

 

Blood glucose, mmol/L

M

5.5 (4.9–7.0)

5.3 (4.9–6.9)

0.812

Renal failure

    

Yes

n

3

4

1.000

No

n

33

30

 

Blood creatinine, μmol/L

M

79 (69–85)

77 (70–85)

0.897

Blood urea, mmol/L

M

5.3 (4.6–6.5)

5.7 (4.6–6.3)

0.668

  1. aData are either given as median (M) with interquartile range or as number of NSCLC patients (n).
  2. bCutoff point at the median plasma FL of all NSCLC patients (1.08 µg/mL AGE-BSA).
  3. cP values were calculated by use of the Student t test (median differences) or the χ2 test (homogeneity of variances) as appropriated.
  4. dADC, adenocarcinoma.
  5. eSCC, squamous cell carcinoma.